Ipca Laboratories (IPCALAB) Fundamentals 2026 — P/E 39.8x, Revenue Analysis | SniperIQ
Ipca Laboratories (IPCALAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹45,358 Crore, trading at ₹1787.65 on the BSE. This SniperIQ fundamentals page covers Ipca Laboratories's valuation (P/E 39.8x, P/B 5.6x), profitability (net margin 11.8%), revenue (₹9,646 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ipca Laboratories's market cap?
Ipca Laboratories (IPCALAB) has a market capitalization of approximately ₹45,358 Crore, trading at ₹1787.65 on the BSE. Market cap moves with the live share price.
What is Ipca Laboratories's P/E ratio?
Ipca Laboratories's trailing twelve-month P/E ratio is 39.8x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ipca Laboratories?
Ipca Laboratories runs a net profit margin of 11.8%, a gross margin of 64.1%, and an operating margin of 24.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ipca Laboratories generate?
Ipca Laboratories reported revenue of ₹9,646 Crore for fiscal year 2026, with net income of ₹1,141 Crore and earnings per share (EPS) of 44.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ipca Laboratories pay a dividend?
Ipca Laboratories offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ipca Laboratories financially healthy?
Ipca Laboratories carries a debt-to-equity ratio of 0.10x and a current ratio of 2.76x, with a market beta of 0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ipca Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ipca Laboratories (IPCALAB) the key facts are: market cap ₹45,358 Crore, P/E 39.8x, revenue ₹9,646 Crore, 52-week range 1252.95-1941.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ipca Laboratories's full fundamentals live
Get Ipca Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.